OTHER
Serum calcium concentrations results
To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism
Status
Unknown
Phase
Not applicable
Enrollment
9
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native and active vitamin D, calcium supplementation and sometimes phosphate binders, with the risk of long term hypercalciuria, nephrocalcinosis and further renal impairment. The use of teriparatide has been reported in adults (daily or bi-daily subcutaneous infusions) and in children (rather continuous subcutaneous infusion) as second-line therapy. The objective of this study is to obtain efficacy and safety data on the use of teriparatide in children with hypoparathyroidism to improve our knowledge of their management.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Oct 15, 2019
Study start
Jun 1, 2019
Primary completion
Jun 2020
Study completion
Dec 2020
Results posted
Not reported
Registry updated
Oct 15, 2019
Outcomes
What the study measures.
Primary outcomes
Serum calcium concentration
Time frame · 3 months after treatment initiation
Secondary outcomes
Serum calcium concentration
Time frame · 1 month after treatment initiation
Serum calcium concentration
Time frame · 6 months after treatment initiation
Serum calcium concentration
Time frame · 12 months after treatment initiation
Serum calcium concentration
Time frame · 3 years after treatment initiation
Eligibility
Who can take part.
- Minimum age
- 2 Years
- Maximum age
- 18 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Patients with hypoparathyroidism * Patients treated with teriparatide * Patients followed in the reference center for calcium and phosphate metabolism diseases of Lyon. * For children under 18: patient and parent (s) / parent having been informed of the study and having expressed their non-opposition Exclusion Criteria: * No social security support
Study locations
1 registered sites.
France. Showing up to 24 locations stored in the fast local snapshot.
Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant
Bron, France
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Teriparatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Sequential Therapies After Osteoanabolic Treatment
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.